Antiviral drugs for influenza

Medical Letter on Drugs and Therapeutics

Volumn 50, Issue 1301-1302, 2008, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

AUTOMUTILATION; AVIAN INFLUENZA; BRONCHOSPASM; CHEMOPROPHYLAXIS; COUGHING; DELIRIUM; DRUG COST; DRUG EFFECT; DRUG INDICATION; HEADACHE; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; NAUSEA; NOSE DISEASE; RECOMMENDED DRUG DOSE; REVIEW; THROAT DISEASE; VOMITING; ANTIVIRAL RESISTANCE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; ENZYMOLOGY; MEDICAL EDUCATION; METABOLISM; QUESTIONNAIRE; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; EDUCATION, MEDICAL, CONTINUING; ENZYME INHIBITORS; HEADACHE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NAUSEA; NEURAMINIDASE; OSELTAMIVIR; QUESTIONNAIRES; VOMITING; ZANAMIVIR;

EID: 58849161265     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. AK Ong and FG Hayden. John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181.
2. L Kaiser et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234.
3. L Kaiser et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667.
4. BL Nordstrom et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21:761.
5. N Lee et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501.
6. A McGeer et al. Outcomes of influenza requiring hospital admission in Ontario, Canada. Clin Infect Dis 2007; 45:1568.
7. TG Sheu et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284.
8. http://www.who.int/csr/disease/influenza/oseltamivir-summary/en/.
9. CDC. Influenza activity - United States and worldwide, 2007-2008 season. MMWR 2008; 57:692.
10. A Lackenby et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:8026.
11. A Moscona and J McKimm-Breschkin. News about influenza B drug resistance that cannot be ignored. JAMA 2007; 297:1492.
12. S Hatakeyama et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435.
13. Neuraminidase Inhibitor Susceptibility Network. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec 2007; 17:149.
14. F Hayden et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005; 10:873.
15. MG Ison et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760.
16. E van der Vries et al. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 2008; 359:1074.
17. JC Williamson and PS Pegram. Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med 2002; 1:85.
18. VM Deyde et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249.
19. AE Fiore et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57 (RR 7):1.
20. Writing Committee of the Second World Health Organization. Update on avian influenza A(H5N1) virus infection in humans. N Engl J Med 2008; 358:261.
21. HJ Schünemann et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21.
22. B Zhou et al. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450.